top of page

Spoonful of technology

Words by Jade Williams

Here, GOLD reviews the top healthcare technology stories of the past few months, highlighting four innovative examples of how companies are harnessing artificial intelligence to benefit key stakeholders

AI-driven medicines firm secures $200m funding dual

Genesis Therapeutics, a pioneer in AI-driven medicines for serious diseases, has closed an oversubscribed $200m Series B funding round. The company will use the funds to take their pipeline of AI-driven medicines through clinical trial testing. It will also help the company to expand, help underserved patients and tackle previously untargeted areas of medicine.

Boehringer Ingelheim brings AI to geographic atrophy

Boehringer Ingelheim and RetinAI are collaborating to accelerate the development of much-needed treatments for geographic atrophy (GA). RetinAI will use its AI tools to analyse Boehringer Ingelheim's imaging datasets from clinical trials to identify novel biomarkers and predictors of disease progression. GA causes profound vision loss in approximately five million people worldwide, with prevalence increasing due to an ageing population.

AI simulation division to pinpoint potential therapies

SandboxAQ, a software-as-a-service company, has announced the launch of a simulation division to drive advances in cancer, Alzheimer's and Parkinson's treatments. The division will focus on reducing the time and cost of developing new therapies and de-risking drug portfolios before products enter the preclinical stage. AstraZeneca and Sanofi have already announced that they will use its AI-powered simulations to identify new therapies.

Within3 introduces new AI to insights platform

Insights platform Within3 is expanding its group engagement applications suite to include an AI-powered moderator assistant. This will deliver 3-7x more real-time feedback, the company says, compared to typical insight gathering methods. The update will also reduce the time and effort required to monitor and analyse the insights gathered, so much so that 23 pharma companies upgraded to the new version in the first week of its availability.

bottom of page